Breccia M - Search Results

1

Ponatinib: A Review of Efficacy and Safety.

Massaro F, Molica M, Breccia M. Massaro F, et al. Among authors: breccia m. Curr Cancer Drug Targets. 2018;18(9):847-856. doi: 10.2174/1568009617666171002142659. Curr Cancer Drug Targets. 2018. PMID: 28969556 Review.

2

Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy.

Alimena G, Breccia M, Latagliata R, Carmosino I, Russo E, Biondo F, Diverio D, Mancini M, Nanni M, Mandelli F. Alimena G, et al. Among authors: breccia m. Cancer. 2006 Sep 1;107(5):1008-13. doi: 10.1002/cncr.22046. Cancer. 2006. PMID: 16878324 Free article.

3

Nilotinib therapy in chronic myelogenous leukemia: the strength of high selectivity on BCR/ABL.

Breccia M, Alimena G. Breccia M, et al. Curr Drug Targets. 2009 Jun;10(6):530-6. doi: 10.2174/138945009788488468. Curr Drug Targets. 2009. PMID: 19519355 Review.

4

Imatinib treatment in chronic myelogenous leukemia: What have we learned so far?

Breccia M, Efficace F, Alimena G. Breccia M, et al. Cancer Lett. 2011 Jan 28;300(2):115-21. doi: 10.1016/j.canlet.2010.10.018. Epub 2010 Nov 12. Cancer Lett. 2011. PMID: 21074936 Review.

5

Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy.

Breccia M, Lo-Coco F. Breccia M, et al. Expert Opin Biol Ther. 2011 Feb;11(2):225-34. doi: 10.1517/14712598.2011.543895. Epub 2010 Dec 11. Expert Opin Biol Ther. 2011. PMID: 21142804 Review.

6

Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome-negative myeloproliferative neoplasms: the Mister Hyde face of a safe drug.

Latagliata R, Spadea A, Cedrone M, Di Giandomenico J, De Muro M, Villivà N, Breccia M, Anaclerico B, Porrini R, Spirito F, Rago A, Avvisati G, Alimena G, Montanaro M, Andriani A; Gruppo Laziale SMPC Ph1 neg. Latagliata R, et al. Among authors: breccia m. Cancer. 2012 Jan 15;118(2):404-9. doi: 10.1002/cncr.26194. Epub 2011 Jun 20. Cancer. 2012. PMID: 21692060 Free article.

7

Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: a systematic review of efficacy and safety data.

Breccia M, Tiribelli M, Alimena G. Breccia M, et al. Crit Rev Oncol Hematol. 2012 Oct;84(1):93-100. doi: 10.1016/j.critrevonc.2012.01.001. Epub 2012 Jan 27. Crit Rev Oncol Hematol. 2012. PMID: 22280914 Review.

8

How to treat CML patients in the tyrosine kinase inhibitors era? From imatinib standard dose to second generation drugs front-line: unmet needs, pitfalls and advantages.

Breccia M, Alimena G. Breccia M, et al. Cancer Lett. 2012 Sep 28;322(2):127-32. doi: 10.1016/j.canlet.2012.03.021. Epub 2012 Mar 23. Cancer Lett. 2012. PMID: 22450750 Review.

9

Evaluation of residual CD34(+) Ph(+) progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during first-line nilotinib therapy.

Defina M, Ippoliti M, Gozzetti A, Abruzzese E, Castagnetti F, Crupi R, Tiribelli M, Breccia M, Salvucci M, Aprile L, Baratè C, Gozzini A, Rosti G, Lauria F, Bocchia M. Defina M, et al. Among authors: breccia m. Cancer. 2012 Nov 1;118(21):5265-9. doi: 10.1002/cncr.27506. Epub 2012 Apr 19. Cancer. 2012. PMID: 22517301 Free article.

10

Suboptimal response in chronic myeloid leukemia patients treated with imatinib: early identification and new therapeutic challenges.

Breccia M, Alimena G. Breccia M, et al. Cancer Lett. 2012 Dec 1;325(1):18-25. doi: 10.1016/j.canlet.2012.05.032. Epub 2012 Jun 6. Cancer Lett. 2012. PMID: 22683475 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

575 results

Search Page